Efzofitimod: meta-analysis of COVID-19 studies

0 0.5 1 1.5+ All studies -291% 1 32 Improvement, Studies, Patients Relative Risk Mortality -291% 1 32 Hospitalization -24% 1 22 RCTs -291% 1 32 Late -291% 1 32 Efzofitimod for COVID-19 c19early.org December 2025 Favorsefzofitimod Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Walker (DB RCT) -291% 3.91 [0.20-74.7] death 2/22 0/10 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.37 Late treatment -291% 3.91 [0.20-74.7] 2/22 0/10 291% higher risk All studies -291% 3.91 [0.20-74.7] 2/22 0/10 291% higher risk 1 efzofitimod COVID-19 study c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.37 Effect extraction pre-specified(most serious outcome) Favors efzofitimod Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Walker (DB RCT) -291% 3.91 [0.20-74.7] 2/22 0/10 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.37 Late treatment -291% 3.91 [0.20-74.7] 2/22 0/10 291% higher risk All studies -291% 3.91 [0.20-74.7] 2/22 0/10 291% higher risk 1 efzofitimod COVID-19 mortality result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.37 Favors efzofitimod Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Walker (DB RCT) -24% 1.24 [0.64-2.42] hosp. time 12 (n) 10 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.53 Late treatment -24% 1.24 [0.64-2.42] 12 (n) 10 (n) 24% higher risk All studies -24% 1.24 [0.64-2.42] 12 (n) 10 (n) 24% higher risk 1 efzofitimod COVID-19 hospitalization result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.53 Favors efzofitimod Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Walker (DB RCT) -11% 1.11 [0.11-10.8] no recov. 2/18 1/10 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.93 Late treatment -11% 1.11 [0.11-10.8] 2/18 1/10 11% higher risk All studies -11% 1.11 [0.11-10.8] 2/18 1/10 11% higher risk 1 efzofitimod COVID-19 recovery result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.93 Favors efzofitimod Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Walker (DB RCT) -291% 3.91 [0.20-74.7] death 2/22 0/10 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.37 Late treatment -291% 3.91 [0.20-74.7] 2/22 0/10 291% higher risk All studies -291% 3.91 [0.20-74.7] 2/22 0/10 291% higher risk 1 efzofitimod COVID-19 Randomized Controlled Trial c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.37 Effect extraction pre-specified(most serious outcome) Favors efzofitimod Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Walker (DB RCT) -291% 3.91 [0.20-74.7] 2/22 0/10 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.37 Late treatment -291% 3.91 [0.20-74.7] 2/22 0/10 291% higher risk All studies -291% 3.91 [0.20-74.7] 2/22 0/10 291% higher risk 1 efzofitimod COVID-19 RCT mortality result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.37 Favors efzofitimod Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Walker (DB RCT) -291% 3.91 [0.20-74.7] death 2/22 0/10 Improvement, RR [CI] Treatment Control Walker (DB RCT) -24% 1.24 [0.64-2.42] hosp. time 12 (n) 10 (n) Walker (DB RCT) -22% 1.22 [0.61-2.44] hosp. time 12 (n) 10 (n) Walker (DB RCT) -56% 1.56 [0.13-17.9] hosp. time 10 (n) 10 (n) Walker (DB RCT) -11% 1.11 [0.11-10.8] no recov. 2/18 1/10 Walker (DB RCT) 17% 0.83 [0.06-11.7] no recov. 1/12 1/10 Walker (DB RCT) -67% 1.67 [0.13-22.0] no recov. 1/6 1/10 Walker (DB RCT) -7% 1.07 [0.11-10.0] no recov. 2/15 1/8 Walker (DB RCT) 20% 0.80 [0.06-10.9] no recov. 1/10 1/8 Walker (DB RCT) -60% 1.60 [0.13-20.2] no recov. 1/5 1/8 Efzofitimod COVID-19 outcomes c19early.org December 2025 Favors efzofitimod Favors control